Amedisys Inc (NASDAQ:AMED) was upgraded by equities research analysts at Mizuho from a “neutral” rating to a “buy” rating in a research note issued to investors on Thursday.

Other research analysts also recently issued research reports about the company. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research note on Friday, September 15th. Jefferies Group LLC restated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research note on Thursday, October 12th. SunTrust Banks, Inc. restated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research note on Monday, October 9th. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada restated a “hold” rating on shares of Amedisys in a research note on Monday, October 23rd. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Amedisys presently has a consensus rating of “Hold” and a consensus price target of $56.20.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. The firm had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.42 EPS.

TRADEMARK VIOLATION NOTICE: “Amedisys Inc (AMED) Upgraded at Mizuho” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2017/11/02/amedisys-inc-amed-upgraded-at-mizuho.html.

In other news, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the transaction, the insider now owns 10,488 shares of the company’s stock, valued at approximately $524,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.00% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. American Century Companies Inc. lifted its position in shares of Amedisys by 41.4% during the 3rd quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock valued at $93,547,000 after buying an additional 489,220 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Amedisys during the 3rd quarter valued at $341,000. First Trust Advisors LP lifted its position in shares of Amedisys by 43.7% during the 3rd quarter. First Trust Advisors LP now owns 38,581 shares of the health services provider’s stock valued at $2,159,000 after buying an additional 11,730 shares during the last quarter. Boston Advisors LLC lifted its position in shares of Amedisys by 3.4% during the 3rd quarter. Boston Advisors LLC now owns 40,731 shares of the health services provider’s stock valued at $2,279,000 after buying an additional 1,354 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its position in shares of Amedisys by 11.2% during the 3rd quarter. Nationwide Fund Advisors now owns 154,763 shares of the health services provider’s stock valued at $8,661,000 after buying an additional 15,541 shares during the last quarter. 96.86% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.